Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Comprehensive geriatric assessment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Comprehensive geriatric assessment. Displaying page 1 of 1.
    EudraCT Number: 2011-002947-83 Sponsor Protocol Number: 40085-75083 Start Date*: 2013-04-26
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Treatment of patients with KRAS wild type advanced colorectal cancer with 5-fluorouracil (5-FU) or 5-FU plus an Epidermal Growth Factor Receptor inhibitor (cetuximab) based on a Comprehensive Geria...
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003185-33 Sponsor Protocol Number: INRCA-02-2011 Start Date*: 2011-10-13
    Sponsor Name:ISTITUTO NAZIONALE DI RICOVERO E CURA PER ANZIANI IRCCS
    Full Title: Prospective, controlled, randomized, blind study to evaluate the effects of intramuscular-paravertebral injections of an oxygen-ozone (O2-O3) mixture in patients with lumbar pain aged 65 or older
    Medical condition: subjects aged 65 or older with lumbar pain and discopathy for at least 6 weeks
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000394-39 Sponsor Protocol Number: KFEAC14.01 Start Date*: 2014-05-05
    Sponsor Name:Odense University Hospital
    Full Title: Full dose S-1 monotherapy compared to reduced dose S-1/oxaliplatin combination therapy as first-line treatment for older patients with metastatic colorectal cancer
    Medical condition: Treatment of older (≥ 70 years) patients with metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NO (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2014-005697-10 Sponsor Protocol Number: FIL_GAEL Start Date*: 2015-04-24
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: GA101-miniCHOP regimen for the treatment of elderly unfit patients with diffuse large B-cell non-Hodgkin’s lymphoma. A phase II study of the Fondazione Italiana Linfomi (FIL).
    Medical condition: Cd20 positive diffuse large B-cell lymphoma in unfit elderly patients
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002855-85 Sponsor Protocol Number: HO135 Start Date*: 2016-03-18
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (...
    Medical condition: Acute Meyloid Leukemia and High Risk Myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) LT (Prohibited by CA)
    Trial results: (No results available)
    EudraCT Number: 2018-000047-31 Sponsor Protocol Number: HOVON155 Start Date*: 2019-09-30
    Sponsor Name:HOVON Foundation
    Full Title: A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) adult AML and high risk myelodysplasia...
    Medical condition: Acute Meyloid Leukemia and high risk myelodysplastic syndromes
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000273-24 Sponsor Protocol Number: RG_19-282 Start Date*: 2020-10-06
    Sponsor Name:University of Birmingham
    Full Title: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 Study
    Medical condition: Acute Myeloid Leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003889-14 Sponsor Protocol Number: NLG-LBC7 Start Date*: 2020-04-07
    Sponsor Name:Skåne University Hospital, Department of Oncology
    Full Title: R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized...
    Medical condition: Diffuse large B-cell lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016661-28 Sponsor Protocol Number: TTD-09-03 Start Date*: 2010-03-16
    Sponsor Name:Grupo Español de Tratamiento de Tumores Digestivos-TTD
    Full Title: Estudio de fase II de panitumumab como agente único de primera línea en pacientes ancianos frágiles con cáncer colorrectal avanzado con KRAS no mutado
    Medical condition: Estudio de fase II de panitumumab como agente único de primera línea en pacientes ancianos frágiles con cáncer colorrectal avanzado con KRAS no mutado
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-001486-27 Sponsor Protocol Number: 1301-LG Start Date*: 2015-05-29
    Sponsor Name:European Orgainzation for the Research and Treatment of Cancer (EORTC)
    Full Title: 10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS...
    Medical condition: Acute Myeloid Leukaemia (AML) in elderly population (equal or older than 60 years).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10024291 Leukaemias acute myeloid HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) LT (Completed) SK (Completed) BG (Completed) NL (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000044-18 Sponsor Protocol Number: GEM2017FIT Start Date*: 2018-07-04
    Sponsor Name:Fundación PETHEMA
    Full Title: Induction therapy with bortezomib-melphalan and prednisone (VMP) followed by lenalidomide and dexamethasone (Rd) versus carfilzomib, lenalidomide and dexamethasone (KRd) plus/minus daratumumab, 18 ...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004474-26 Sponsor Protocol Number: FIL_PREVID Start Date*: 2020-08-12
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL). A randomized, open label, phase III s...
    Medical condition: Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-003560-21 Sponsor Protocol Number: REAL 07 CC5013 STUDY ID LR-CHOP21 Start Date*: 2007-09-20
    Sponsor Name:GIMURELL
    Full Title: Prospective multicenter phase I-II pilot trial to evaluate efficacy and safety of treatment with Lenalidomide plus R-CHOP21 (LR-CHOP21) for elderly patients with untreated Diffuse Large B-Cell Lymp...
    Medical condition: patient with BDLCL elderly untreated
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012825 PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:09:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA